A Phase I Trial to Evaluate COTI-2 in Combination with Eribulin in the Second or Subsequent Line Therapy of Patients with Triple Negative Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs COTI 2 (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 22 May 2019 According to a Cotinga Pharmaceuticals media release, the company intends to use the proceeds from the latest offering to fund the initiation of this trial (triple negative breast cancer, COTI-2 in combination with eribulin).
- 05 Nov 2018 According to a Cotinga Pharmaceuticals media release, the company has entered into a research collaboration with St. Vincent's University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer.
- 09 Oct 2018 New trial record